Selexis to Exhibit at BIO Taiwan 2013
Selexis to Meet with Companies Interested in Protein Drug Discovery, Cell Line Development and Lead Identification for Therapeutic Drug Development and Manufacturing
Geneva, Switzerland (PRWEB) July 16, 2013
Selexis SA, a serial innovation company focused on drug discovery for lead identification and cell line development for scale-up and manufacturing of therapeutic protein drugs, announced today that representatives from the Company will be participating in the BIO Taiwan 2013 conference being held July 18 – 21, 2013 at Taipei Word Trade Center – Nangang Exhibition Hall in Nangang, Taipei, Taiwan.
Selexis has partnerships and commercial deals with leading biotechnology and pharmaceutical companies worldwide. The Selexis SUREtechnology Platform™ offers a range of solutions for recombinant protein expression and protein therapeutic development, including technologies and expression libraries for overcoming a wide range of secretion bottlenecks, screening platforms to facilitate lead identification of clinical candidates and development of high producing clonal cell lines for therapeutic protein programs. Selexis’ SUREtechnology Platform™ can be applied from early drug discovery to cGMP manufacturing, resulting in faster, more reliable, higher-expressing mammalian cell lines that can be applied to a wide range of areas such as diagnostics, drug discovery, therapeutics and bio-manufacturing.
Representatives will be available to discuss Selexis’ capabilities. Companies or individuals attending BIO Taiwan 2013 can meet with Selexis representatives at the BioAlps Lake Geneva Life Science Cluster booth number I216-218.
For more information, please visit http://www.bioclub.com.tw/en/vis_info.asp
About Selexis SA
Headquartered in Geneva, Switzerland, Selexis SA is a global life science company with innovative technologies and world-class expert services for drug discovery, cell line development and scale-up to manufacturing of therapeutic proteins. The Company’s SUREtechnology Platform™ is based on Selexis Genetic Elements™ — novel DNA-based elements that control the dynamic organization of chromatin within all mammalian cells and allow for higher and more stable expression of recombinant proteins. Selexis generated cell lines are being used in a variety of programs from drug discovery to late-stage clinical trials.
For more information:
- Visit http://www.selexis.com
- Follow us on Twitter @selexisSA
- Become a fan at http://www.facebook.com/SelexisSA
For the original version on PRWeb visit: http://www.prweb.com/releases/selexis_bio_taiwan/cell_line_development/prweb10927923.htm